Which hedge funds own TXG? 10X GENOMICS INC, Q2 2026 13F holders
Healthcare · Open on the interactive board
10 of the hedge funds tracked by WhaleCreep disclosed a position in TXG (10X GENOMICS INC) in their Q2 2026 13F filings, worth $314.2m in total. The largest holder by portfolio weight is Casdin Capital at 2.0% of its book. 3 managers opened a new position this quarter: Anomaly Capital Management, Duquesne Family Office LLC, Point72 Asset Management LP. 2 exited: Ancora Advisors, Marshall Wace.
10tracked managers holding
3opened this quarter
2exited this quarter
Which hedge funds hold TXG? Current holders by portfolio weight
| Manager | As of | Weight of book | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|
| Casdin Capital | Q2 2026 | 2.0% | $40.3m | 1,050,000 | -54% | reduced |
| Anomaly Capital Management | Q2 2026 | 1.3% | $33.3m | 867,794 | – | new |
| Duquesne Family Office LLC | Q2 2026 | 0.4% | $15.5m | 403,100 | – | new |
| Point72 Asset Management LP | Q2 2026 | 0.1% | $71.0m | 1,852,776 | – | new |
| Citadel Advisors | Q2 2026 | 0.1% | $106.6m | 2,779,213 | 274% | added |
| Renaissance Technologies LLC | Q2 2026 | 0.0% | $30.8m | 802,039 | -20% | reduced |
| Brevan Howard Capital Management | Q2 2026 | 0.0% | $3.0m | 77,803 | 201% | added |
| D. E. Shaw & Co | Q2 2026 | 0.0% | $8.9m | 233,069 | 240% | added |
| Millennium Management | Q2 2026 | 0.0% | $4.5m | 116,833 | -94% | reduced |
| Bridgewater Associates | Q2 2026 | 0.0% | $512.8k | 13,375 | -62% | reduced |
Exited since the previous quarter
| Manager | Prior weight | Prior value |
|---|---|---|
| Ancora Advisors | 0.0% | $38.1k |
| Marshall Wace | 0.1% | $2.2m |
How has hedge fund ownership of TXG changed?
| Quarter | Managers holding | Combined value |
|---|---|---|
| Q2 2026 | 10 | $314.2m |
| Q1 2026 | 9 | $134.4m |
| Q4 2025 | 4 | $51.0m |
| Q3 2025 | 3 | $13.7m |
| Q2 2025 | 4 | $23.8m |
| Q1 2025 | 4 | $25.0m |
| Q4 2024 | 4 | $55.7m |
| Q3 2024 | 4 | $36.0m |
| Q2 2024 | 5 | $159.2m |
| Q1 2024 | 6 | $426.8m |
| Q4 2023 | 6 | $772.0m |
| Q3 2023 | 8 | $647.5m |
| Q2 2023 | 6 | $983.0m |
| Q1 2023 | 8 | $952.1m |
| Q4 2022 | 7 | $435.3m |
| Q3 2022 | 5 | $457.4m |
Counts every tracked manager that disclosed TXG in that quarter's filing, including managers that have since stopped filing.